{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:54:58Z","timestamp":1785884098235,"version":"3.56.0"},"reference-count":23,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disord Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Continuous subcutaneous apomorphine infusion (CSAI) is effective in Parkinson's disease but has not been evaluated in multiple system atrophy (MSA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the 6\u2010month efficacy and tolerability of CSAI in MSA patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>French multicenter retrospective registry\u2010based analysis of CSAI use in MSA. The primary outcome was the 6\u2010month clinical response using the Clinical Global Impression Improvement (CGI\u2010I) scale. Secondary outcomes included tolerability, indications, infusion parameters, and treatment course.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty patients were included; 94% had MSA\u2010P. All had motor fluctuations and 88% showed a clinically meaningful dopaminergic response. CSAI was initiated for motor symptoms (100%) or pain (54%). At 6 months, most patients improved (36% \u201cmuch,\u201d 54% \u201cminimally\u201d), mainly due to reduced motor fluctuations. Only 8% discontinued CSAI. Tolerability was rated good\/excellent in 74%; 20% reported somnolence and\/or orthostatic hypotension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In selected MSA patients with partial dopaminergic responsiveness and motor fluctuations, CSAI provided short\u2010term clinical benefit with acceptable tolerability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mdc3.70644","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:31:56Z","timestamp":1776663116000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Continuous Apomorphine Infusion in Multiple System Atrophy Real\u2010World Insights From a French Nationwide Retrospective Cohort"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9303-3642","authenticated-orcid":false,"given":"Simon","family":"Lamy","sequence":"first","affiliation":[{"name":"Department of Neurology Pontchaillou University Hospital  Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederique","family":"Leh","sequence":"additional","affiliation":[{"name":"Department of Neurology Pontchaillou University Hospital, CIC INSERM 1414 Rennes  Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Foubert\u2010Samier","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, Service de Neurologie des Maladies Neurod\u00e9g\u00e9n\u00e9ratives, IMNc, CRMR AMS  Bordeaux France"},{"name":"Universit\u00e9 de Bordeaux, CNRS, IMN, UMR5293  Bordeaux France"},{"name":"Bordeaux Population Health Research Center, Inserm U1219, University of Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soizic","family":"Leguy Bonnet","sequence":"additional","affiliation":[{"name":"Cabinet de Neurologie Lib\u00e9rale  Saint\u2010Malo France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0248-5772","authenticated-orcid":false,"given":"Guillaume","family":"Baille","sequence":"additional","affiliation":[{"name":"Department of Neurology Rothschild Foundation Hospital  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Fabbri","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Neurosciences, Toulouse Parkinson Expert Centre, Toulouse NeuroToul Center of Excellence in Neurodegeneration (COEN), French NS\u2010Park\/F\u2010CRIN Network University of Toulouse 3, CHU of Toulouse, INSERM  Toulouse France"},{"name":"Toulouse NeuroImaging Center University of Toulouse, Inserm, UPS  Toulouse France"},{"name":"MSA French Reference Center Univ. Hospital Toulouse  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaux","family":"Dunoyer","sequence":"additional","affiliation":[{"name":"Department of Neurology CRMR MSA, Piti\u00e9\u2010Salp\u00eatri\u00e8re Hospital, APHP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Mantisi","sequence":"additional","affiliation":[{"name":"Department of Neurology\u2010Parkinson's Disease Expert Center Institute of Neurology, AP\u2010HP, Piti\u00e9\u2010Salp\u00eatri\u00e8re University Hospital  Paris France"},{"name":"H\u00f4pitaux de Paris (AP\u2010HP) Piti\u00e9\u2010Salp\u00eatri\u00e8re Hospital  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Giordana","sequence":"additional","affiliation":[{"name":"Department of Neurology, NS\u2010PARK\/FCRIN Network Centre Hospitalier Universitaire de Nice, Universit\u00e9 C\u00f4te d'Azur  Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"El Ouartassi","sequence":"additional","affiliation":[{"name":"Neurology Department Centre Hospitalier d'Antibes  Antibes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[{"name":"French National Reference Center for MSA, Clinical Investigation Centre CIC1436, Department of Neurosciences and Clinical Pharmacology, and NS\u2010Park\/FCRIN Network University of Toulouse, University Hospital of Toulouse, INSERM  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2172-7527","authenticated-orcid":false,"given":"Wassilios G.","family":"Meissner","sequence":"additional","affiliation":[{"name":"Department of Neurology for Neurodegenerative Diseases University Hospital Bordeaux  Bordeaux France"},{"name":"Institute for Neurodegenerative Diseases CNRS UMR 5293, University Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bendetowicz","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, Service de Neurologie des Maladies Neurod\u00e9g\u00e9n\u00e9ratives, IMNc, CRMR AMS  Bordeaux France"},{"name":"Universit\u00e9 de Bordeaux, CNRS, IMN, UMR5293  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Vanel","sequence":"additional","affiliation":[{"name":"Cabinet de neurologie  Cesson S\u00e9vign\u00e9 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Grabli","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Paris Brain Institute, Inserm, CNRS  Paris France"},{"name":"Department of Neurology Piti\u00e9\u2010Salp\u00eatri\u00e8re Hospital, APHP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Ory\u2010Magne","sequence":"additional","affiliation":[{"name":"Department of Neurology, Toulouse Parkinson Expert Centre INSERM, UMR1214 Toulouse NeuroImaging Centre TONIC, University Hospital of Toulouse  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Drapier","sequence":"additional","affiliation":[{"name":"Department of Neurology Pontchaillou University Hospital, CIC INSERM 1414 Rennes  Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,19]]},"reference":[{"issue":"1","key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-022-00382-6","article-title":"Multiple system atrophy","volume":"8","author":"Poewe W","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"e_1_2_10_3_1","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/mds.29005","article-title":"The Movement Disorder Society criteria for the diagnosis of multiple system atrophy","volume":"37","author":"Wenning GK","year":"2022","journal-title":"Mov Disord"},{"issue":"3","key":"e_1_2_10_4_1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S1474-4422(12)70327-7","article-title":"The natural history of multiple system atrophy: a prospective European cohort study","volume":"12","author":"Wenning GK","year":"2013","journal-title":"Lancet Neurol"},{"key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.parkreldis.2022.03.002","article-title":"Deep brain stimulation for atypical parkinsonism: a systematic review on efficacy and safety","volume":"96","author":"Artusi CA","year":"2022","journal-title":"Parkinsonism Relat Disord"},{"key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.parkreldis.2022.05.018","article-title":"Use of levodopa\u2010carbidopa intestinal gel to treat patients with multiple system atrophy","volume":"100","author":"Blaise AS","year":"2022","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman S","year":"2008","journal-title":"Neurology"},{"issue":"15","key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson's disease","volume":"25","author":"Tomlinson CL","year":"2010","journal-title":"Mov Disord"},{"issue":"7","key":"e_1_2_10_9_1","first-page":"28","article-title":"The clinical global impressions scale","volume":"4","author":"Busner J","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"issue":"8","key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/mds.22063","article-title":"Efficacy of long\u2010term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study","volume":"23","author":"Garc\u00eda Ruiz PJ","year":"2008","journal-title":"Mov Disord"},{"issue":"9","key":"e_1_2_10_11_1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","article-title":"Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double\u2010blind, randomised, placebo\u2010controlled trial","volume":"17","author":"Katzenschlager R","year":"2018","journal-title":"Lancet Neurol"},{"issue":"6","key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00415-016-8106-3","article-title":"Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study","volume":"263","author":"Drapier S","year":"2016","journal-title":"J Neurol"},{"issue":"5","key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S1474-4422(22)00085-0","article-title":"Safety and efficacy of subcutaneous night\u2010time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double\u2010blind crossover study","volume":"21","author":"De Cock VC","year":"2022","journal-title":"Lancet Neurol"},{"issue":"12","key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/mdc3.13907","article-title":"Apomorphine at the end\u2010of\u2010life\u2014a role to play","volume":"10","author":"Azoia C","year":"2023","journal-title":"Mov Disord Clin Pract"},{"issue":"8","key":"e_1_2_10_15_1","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1177\/0269216309106979","article-title":"The pragmatic use of apomorphine at the end of life","volume":"23","author":"Dewhurst F","year":"2009","journal-title":"Palliat Med"},{"issue":"1","key":"e_1_2_10_16_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3233\/JPD-230201","article-title":"Terminal Care in Parkinson's disease: real\u2010life use of continuous subcutaneous apomorphine infusion to improve patient comfort","volume":"14","author":"B\u00e9reau M","year":"2024","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"e_1_2_10_17_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2025.107837","article-title":"Other clinical uses for apomorphine: sedation and sleep disorders, withdrawal of oral dopaminergic medication, palliative care, restless legs syndrome, traumatic brain injury, sexual dysfunction","volume":"139","author":"V\u00e9rin M","year":"2025","journal-title":"Parkinsonism Relat Disord"},{"issue":"7345","key":"e_1_2_10_18_1","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/bmj.324.7345.1072","article-title":"Effects of community based nurses specialising in Parkinson's disease on health outcome and costs: randomised controlled trial","volume":"324","author":"Jarman B","year":"2002","journal-title":"BMJ"},{"key":"e_1_2_10_19_1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/bs.irn.2022.04.005","article-title":"Covid\u201019 and Parkinson's disease: nursing care, vaccination and impact on advanced therapies","volume":"165","author":"Roszmann A","year":"2022","journal-title":"Int Rev Neurobiol"},{"issue":"1","key":"e_1_2_10_20_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2025.107866","article-title":"A delphi consensus statement about French practical management of continuous apomorphine infusion in patients with Parkinson's disease and motor fluctuations","volume":"139","author":"Ory Magne F","year":"2025","journal-title":"Parkinsonism Relat Disord"},{"key":"e_1_2_10_21_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-025-01206-6","article-title":"Revisiting the 2015 MDS diagnostic criteria for Parkinson disease: insights from autopsy\u2010confirmed cases","volume":"11","author":"Fox SH","year":"2025","journal-title":"NPJ Park Dis"},{"issue":"2","key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/1877718X241310727","article-title":"Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: results from the phase 3, long\u2010term, open\u2010label United States InfusON study","volume":"15","author":"Isaacson SH","year":"2025","journal-title":"J Parkinsons Dis"},{"key":"e_1_2_10_23_1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.parkreldis.2021.11.026","article-title":"Subcutaneous apomorphine in the treatment of progressive supranuclear palsy and corticobasal syndrome: a preliminary study of 7 cases","volume":"95","author":"Hubsch C","year":"2022","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"e_1_2_10_24_1","first-page":"1","article-title":"Long\u2010term effect of apomorphine infusion in advanced Parkinson's disease: a real\u2010life study","volume":"7","author":"Meira B","year":"2021","journal-title":"NPJ Park Dis"}],"container-title":["Movement Disorders Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.70644","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mdc3.70644","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.70644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:31:59Z","timestamp":1776663119000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mdc3.70644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,19]]},"references-count":23,"alternative-id":["10.1002\/mdc3.70644"],"URL":"https:\/\/doi.org\/10.1002\/mdc3.70644","archive":["Portico"],"relation":{},"ISSN":["2330-1619","2330-1619"],"issn-type":[{"value":"2330-1619","type":"print"},{"value":"2330-1619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,19]]},"assertion":[{"value":"2025-10-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"mdc3.70644"}}